
Dr Pascal Mancuso is a Urological Surgeon with consulting rooms in Campbelltown, Liverpool and Bowral. He attained his medical degree at The University of New South Wales and graduated with Honours representing Academic Excellence. After years of rigorous and comprehensive urological training undertaken in both Australia and England, Dr Mancuso has now sharpened his focus and specializes in Robotic surgery for Prostate and Kidney Cancer, as well as minimally invasive treatment options for Prostatic Enlargement and Kidney Stones. Dr Mancuso offers surgery for his patients at Campbelltown Public and Private Hospitals, Liverpool Public and Private Hospitals, Southern Highlands Private Hospital and the Chris O’Brien Lifehouse. As the Head of the Urology Department at Liverpool Hospital, Dr Mancuso prides himself on promoting a department that is at the leading edge of research and technology. Since commencing the Head of Department role in 2015, Dr Mancuso has been integral in the commencement of Robotic Surgery at the Hospital for Prostate and Kidney Cancer. Indeed he is one of only a select group of Urologists who have been credentialed to offer Robotic Surgery at the hospital. Dr Mancuso was also actively involved in the planning and presentation of the Liverpool Hospital Robotics Summit where he was chosen to undertake Live Surgery with his Nerve Sparing Robotic Prostatectomy televised live to the Auditorium and observed by over 100 doctors, nurses and students.
Selected publications from PubMed
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
Siva S, Pryor D, Martin J, Hardcastle N, Moon D, Kron T, Higgs B, Foroudi F, Ruben J, Sridharan S, Montgomery R, Davey R, Lin C, Shaw M, Lawrentschuk N, Appu S, Vanneste BGL, Hofman MS, Murphy DG, De Abreu Lourenco R, Mancuso P, Brook NR, Raman A, Wong LM, Sidhom M, Wood S, Ali M, Bressel M
Lancet Oncol. 2026 Jun;27(6):711-720 doi: 10.1016/S1470-2045(26)00091-4.
Prolonged life-threatening anaphylaxis to Floseal during partial nephrectomy: A case report.
McClintock G, Frishling D, Lam Y, Mancuso P
Curr Urol. 2025 May;19(3):198-200 doi: 10.1097/CU9.0000000000000200.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D, FASTRACK II Investigator Group
Lancet Oncol. 2024 Mar;25(3):308-316 doi: 10.1016/S1470-2045(24)00020-2.
Encouraging Patients to Ask Questions: Development and Pilot Testing of a Question Prompt List for Patients Undergoing a Biopsy for Suspected Prostate Cancer.
Rincones O, Smith A', Chong P, Mancuso P, Wu VS, Sidhom M, Wong K, Ngo D, Gassner P, Girgis A
Curr Oncol. 2023 Feb 8;30(2):2088-2104 doi: 10.3390/curroncol30020162.
COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital.
Best OV, Armany D, Murthy V, Handmer M, Mancuso P
ANZ J Surg. 2021 Dec;91(12):2800-2805 doi: 10.1111/ans.17102.
Help your network discover Dr. Pascal Mancuso's clinical expertise.